It is not a stretch to say immunotherapy is the future of cancer treatment. Some estimates put the sale of immunotherapy drugs at $50 billion by the middle of the next decade (up from $6 billion in 2016).
The proven success of combining immune system checkpoint inhibitors (ICIs) with oncolytic vaccines and SMAC mimetics is leading to strategic partnerships between pharmaceutical companies large and small.
New payload delivery systems that use microbiota may shake up the sector in the coming years.
“I cannot imagine that, during the next 10 years, we won’t start to see a dramatic change in the long-term survival of many of the patients with many of the cancers,” says Jeff Bluestone, Director of the UCSF Hormone Research Institute.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.